Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer
Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.
ADT Therapy in Prostate Cancer: Agonists vs Antagonists
Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.
Overview on Androgen Deprivation Therapy in Prostate Cancer
A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.
Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer
Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.
Anjali Hari, MD, Speaks to Survival/Safety Outcomes With HIPEC in Frail and Non-Frail Ovarian Cancer
Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.
First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial
A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.
Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM
Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Trends in Prostate Cancer Care
Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.
Patient-Healthcare Provider Communication Regarding Challenges
A prostate cancer expert reemphasizes importance of open communication between patients and healthcare providers.
Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC
A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.
In-Class Transition From Bortezomib to Ixazomib in MM: ASH 2021 Update
Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.
Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy
A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.
IRd in Multiple Myeloma: Patient-Reported Adherence and Outcomes
Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers
Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.
Ursula A. Matulonis, MD, Discusses Rationale for Assessing Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
Ursula A. Matulonis, MD, highlights the rationale behind studying mirvetuximab soravtansine (IMGN853) as a therapy for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer
Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.
